{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T21:42:13Z","timestamp":1789076533763,"version":"build-2803163510"},"reference-count":162,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Chemico-Biological Interactions"],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.1016\/j.cbi.2023.110470","type":"journal-article","created":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T19:11:52Z","timestamp":1680376312000},"page":"110470","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":28,"special_numbering":"C","title":["Protease-activated receptors in kidney diseases: A comprehensive review of pathological roles, therapeutic outcomes and challenges"],"prefix":"10.1016","volume":"377","author":[{"given":"Newly","family":"Bagang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kirti","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4032-9049","authenticated-orcid":false,"given":"Gaaminepreet","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sri Harsha","family":"Kanuri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sidharth","family":"Mehan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"16","key":"10.1016\/j.cbi.2023.110470_bib1","doi-asserted-by":"crossref","first-page":"2733","DOI":"10.1042\/BCJ20170272","article-title":"Protease-activated receptor-2 promotes kidney tubular epithelial inflammation by inhibiting autophagy via the PI3K\/Akt\/mTOR signaling pathway","volume":"474","author":"Du","year":"2017","journal-title":"Biochem. J."},{"issue":"6","key":"10.1016\/j.cbi.2023.110470_bib2","doi-asserted-by":"crossref","first-page":"F1140","DOI":"10.1152\/ajprenal.00460.2016","article-title":"Protease-activated receptors in kidney disease progression","volume":"311","author":"Palygin","year":"2016","journal-title":"Am. J. Physiol. Ren. Physiol."},{"issue":"2","key":"10.1016\/j.cbi.2023.110470_bib3","doi-asserted-by":"crossref","DOI":"10.1152\/physrev.00028.2003","article-title":"Protease-activated receptors: contribution to physiology and disease","volume":"84","author":"Ossovskaya","year":"2004","journal-title":"Physiol. Rev."},{"issue":"1","key":"10.1016\/j.cbi.2023.110470_bib4","doi-asserted-by":"crossref","DOI":"10.1038\/srep33030","article-title":"Protease-activated receptor-1 deficiency protects against streptozotocin-induced diabetic nephropathy in mice","volume":"6","author":"Waasdorp","year":"2016","journal-title":"Sci. Rep."},{"issue":"11","key":"10.1016\/j.cbi.2023.110470_bib5","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1038\/nm1667","article-title":"Activated protein C protects against diabetic nephropathy by inhibiting endothelial and podocyte apoptosis","volume":"13","author":"Isermann","year":"2007","journal-title":"Nat. Med."},{"key":"10.1016\/j.cbi.2023.110470_bib6","doi-asserted-by":"crossref","first-page":"151","DOI":"10.3389\/fendo.2014.00151","article-title":"Molecular and cellular events mediating glomerular podocyte dysfunction and depletion in diabetes mellitus","volume":"5","author":"Anil Kumar","year":"2014","journal-title":"Front. Endocrinol."},{"issue":"8","key":"10.1016\/j.cbi.2023.110470_bib7","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1097\/00007890-200110270-00018","article-title":"Protease activated receptor and plasminogen activator inhibitor 1 expression in chronic allograft nephropathy: the role of coagulation and fibrinolysis in renal graft fibrosis1","volume":"72","author":"Grandaliano","year":"2001","journal-title":"Transplantation"},{"issue":"17","key":"10.1016\/j.cbi.2023.110470_bib8","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1001\/jama.298.17.2038","article-title":"Prevalence of chronic kidney disease in the United States","volume":"298","author":"Coresh","year":"2007","journal-title":"JAMA"},{"key":"10.1016\/j.cbi.2023.110470_bib9","article-title":"Tissue factor, blood coagulation, and beyond: an overview","author":"Chu","year":"2011","journal-title":"Int. J. Inflamm."},{"issue":"8","key":"10.1016\/j.cbi.2023.110470_bib10","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1093\/ndt\/16.8.1529","article-title":"Role of thrombin receptors in the kidney: lessons from PAR1 knock\u2010out mice","volume":"16","author":"Rondeau","year":"2001","journal-title":"Nephrol. Dial. Transplant."},{"issue":"7","key":"10.1016\/j.cbi.2023.110470_bib11","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1016\/j.bbadis.2012.12.013","article-title":"Coagulation and coagulation signaling in fibrosis","volume":"1832","author":"Mercer","year":"2013","journal-title":"Biochim Biophys Acta Mol Basis Dis BBA-MOL BASIS DIS."},{"issue":"10","key":"10.1016\/j.cbi.2023.110470_bib12","doi-asserted-by":"crossref","first-page":"10966","DOI":"10.1096\/fj.201900516R","article-title":"Pharmacological PAR\u20101 inhibition reduces blood glucose levels but does not improve kidney function in experimental type 2 diabetic nephropathy","volume":"33","author":"Waasdorp","year":"2019","journal-title":"Faseb. J."},{"issue":"4","key":"10.1016\/j.cbi.2023.110470_bib13","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1007\/s11154-008-9100-6","article-title":"New insights into the mechanisms of fibrosis and sclerosis in diabetic nephropathy","volume":"9","author":"Brosius","year":"2008","journal-title":"Rev. Endocr. Metab. Disord."},{"issue":"1","key":"10.1016\/j.cbi.2023.110470_bib14","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1478-811X-11-86","article-title":"Proteinase-activated receptors (PARs)\u2013focus on receptor-receptor-interactions and their physiological and pathophysiological impact","volume":"11","author":"Gieseler","year":"2013","journal-title":"Cell Commun. Signal."},{"issue":"1","key":"10.1016\/j.cbi.2023.110470_bib15","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1053\/j.ajkd.2011.09.017","article-title":"Relative incidence of ESRD versus cardiovascular mortality in proteinuric type 2 diabetes and nephropathy: results from the DIAMETRIC (Diabetes Mellitus Treatment for Renal Insufficiency Consortium) database","volume":"59","author":"Packham","year":"2012","journal-title":"Am. J. Kidney Dis."},{"issue":"2","key":"10.1016\/j.cbi.2023.110470_bib16","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1136\/thoraxjnl-2013-203877","article-title":"Targeting protease activated receptor-1 with P1pal-12 limits bleomycin-induced pulmonary fibrosis","volume":"69","author":"Lin","year":"2014","journal-title":"Thorax"},{"issue":"1","key":"10.1016\/j.cbi.2023.110470_bib17","doi-asserted-by":"crossref","first-page":"G226","DOI":"10.1152\/ajpgi.00444.2007","article-title":"Protease-activated receptor 1 knockout reduces experimentally induced liver fibrosis","volume":"294","author":"Rullier","year":"2008","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"issue":"1","key":"10.1016\/j.cbi.2023.110470_bib18","doi-asserted-by":"crossref","first-page":"410","DOI":"10.2119\/molmed.2014.00027","article-title":"Protease activated receptor-1 deficiency diminishes bleomycin-induced skin fibrosis","volume":"20","author":"Duitman","year":"2014","journal-title":"Mol. Med."},{"issue":"11","key":"10.1016\/j.cbi.2023.110470_bib19","doi-asserted-by":"crossref","first-page":"3365","DOI":"10.1681\/ASN.2004090740","article-title":"Acute kidney injury, mortality, length of stay, and costs in hospitalized patients","volume":"16","author":"Chertow","year":"2005","journal-title":"J. Am. Soc. Nephrol."},{"issue":"2","key":"10.1016\/j.cbi.2023.110470_bib20","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/S0031-6997(24)01493-5","article-title":"Proteinase-activated receptors","volume":"53","author":"Macfarlane","year":"2001","journal-title":"Pharmacol. Rev."},{"issue":"8","key":"10.1016\/j.cbi.2023.110470_bib21","doi-asserted-by":"crossref","first-page":"2072","DOI":"10.1097\/01.ASN.0000080315.37254.A1","article-title":"Protease-activated receptor-2 expression in IgA nephropathy: a potential role in the pathogenesis of interstitial fibrosis","volume":"14","author":"Grandaliano","year":"2003","journal-title":"J. Am. Soc. Nephrol."},{"issue":"4","key":"10.1016\/j.cbi.2023.110470_bib22","doi-asserted-by":"crossref","first-page":"F654","DOI":"10.1152\/ajprenal.00489.2018","article-title":"Protease-activated receptor 2 exacerbates cisplatin-induced nephrotoxicity","volume":"316","author":"Watanabe","year":"2019","journal-title":"Am. J. Physiol. Ren. Physiol."},{"key":"10.1016\/j.cbi.2023.110470_bib23","doi-asserted-by":"crossref","first-page":"398","DOI":"10.3389\/fcell.2020.00398","article-title":"Cathepsin S and protease-activated receptor-2 drive alloimmunity and immune regulation in kidney allograft rejection","volume":"8","author":"Lei","year":"2020","journal-title":"Front. Cell Dev. Biol."},{"issue":"3","key":"10.1016\/j.cbi.2023.110470_bib24","doi-asserted-by":"crossref","first-page":"593","DOI":"10.3892\/ijmm.2016.2464","article-title":"Evolution of the protease-activated receptor family in vertebrates","volume":"37","author":"Jin","year":"2016","journal-title":"Int. J. Mol. Med."},{"issue":"13","key":"10.1016\/j.cbi.2023.110470_bib25","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1038\/sj.onc.1204194","article-title":"Protease activated receptors: theme and variations","volume":"20","author":"O'Brien","year":"2001","journal-title":"Oncogene"},{"issue":"1","key":"10.1016\/j.cbi.2023.110470_bib26","first-page":"1","article-title":"Protease-activated receptors (PARs): mechanisms of action and potential therapeutic modulators in PAR-driven inflammatory diseases","volume":"17","author":"Heuberger","year":"2019","journal-title":"Thromb. J."},{"key":"10.1016\/j.cbi.2023.110470_bib27","article-title":"PAR1 antagonists: an emerging antiplatelet drug class","volume":"vol. 148","author":"Pan","year":"2016"},{"key":"10.1016\/j.cbi.2023.110470_bib28","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s12959-019-0194-8","article-title":"Protease-activated receptors (PARs): mechanisms of action and potential therapeutic modulators in PAR-driven inflammatory diseases","volume":"17","author":"Heuberger","year":"2019","journal-title":"Thromb. J."},{"key":"10.1016\/j.cbi.2023.110470_bib29","doi-asserted-by":"crossref","first-page":"67","DOI":"10.3389\/fendo.2014.00067","article-title":"Biased signaling of protease-activated receptors","volume":"5","author":"Zhao","year":"2014","journal-title":"Front. Endocrinol."},{"issue":"2","key":"10.1016\/j.cbi.2023.110470_bib30","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1186\/cc1825","article-title":"Science review: role of coagulation protease cascades in sepsis","volume":"7","author":"Riewald","year":"2003","journal-title":"Crit. Care"},{"issue":"10","key":"10.1016\/j.cbi.2023.110470_bib31","doi-asserted-by":"crossref","first-page":"5255","DOI":"10.1073\/pnas.97.10.5255","article-title":"Tissue factor-and factor X-dependent activation of protease-activated receptor 2 by factor VIIa","volume":"97","author":"Camerer","year":"2000","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"3","key":"10.1016\/j.cbi.2023.110470_bib32","first-page":"874","article-title":"Cytoprotective signaling by activated protein C requires protease-activated receptor-3 in podocytes","volume":"119","author":"Madhusudhan","year":"2012","journal-title":"Blood- J. Am. Soc. Hematol."},{"issue":"6","key":"10.1016\/j.cbi.2023.110470_bib33","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1002\/iub.447","article-title":"The occupancy of endothelial protein C receptor by its ligand modulates the par\u20101 dependent signaling specificity of coagulation proteases","volume":"63","author":"Rezaie","year":"2011","journal-title":"IUBMB Life"},{"issue":"1","key":"10.1016\/j.cbi.2023.110470_bib34","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1002\/ddr.10318","article-title":"Proteinase\u2010activated receptors (PARs) and the kidney","volume":"60","author":"Hollenberg","year":"2003","journal-title":"Drug Dev. Res."},{"issue":"1","key":"10.1016\/j.cbi.2023.110470_bib35","doi-asserted-by":"crossref","first-page":"F95","DOI":"10.1152\/ajprenal.00396.2002","article-title":"Bidirectional regulation of renal hemodynamics by activation of PAR1 and PAR2 in isolated perfused rat kidney","volume":"285","author":"Gui","year":"2003","journal-title":"Am. J. Physiol. Ren. Physiol."},{"issue":"1","key":"10.1016\/j.cbi.2023.110470_bib36","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1111\/j.1440-1797.2006.00746.x","article-title":"Potential physiological and pathophysiological roles for protease\u2010activated receptor\u20102 in the kidney","volume":"12","author":"Vesey","year":"2007","journal-title":"Nephrology"},{"key":"10.1016\/j.cbi.2023.110470_bib37","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1159\/000490118","article-title":"What is the role of soluble urokinase-type plasminogen activator in renal disease?","volume":"139","author":"Saleem","year":"2018","journal-title":"Nephron"},{"issue":"3","key":"10.1016\/j.cbi.2023.110470_bib38","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1172\/JCI115104","article-title":"Sites of synthesis of urokinase and tissue-type plasminogen activators in the murine kidney","volume":"87","author":"Sappino","year":"1991","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.cbi.2023.110470_bib39","doi-asserted-by":"crossref","first-page":"5462","DOI":"10.2741\/3093","article-title":"Urokinase and its receptors in chronic kidney disease","volume":"13","author":"Zhang","year":"2008","journal-title":"Front. Biosci."},{"issue":"3\u20134","key":"10.1016\/j.cbi.2023.110470_bib40","doi-asserted-by":"crossref","first-page":"161","DOI":"10.3109\/08860228709047651","article-title":"Urinary kallikrein excretion in chronic renal failure: relationship to blood pressure and the acute effect of captopril","volume":"10","author":"Cumming","year":"1987","journal-title":"Ren. Fail."},{"issue":"6","key":"10.1016\/j.cbi.2023.110470_bib41","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1172\/JCI113254","article-title":"Abnormal regulation of renal kallikrein in experimental diabetes. Effects of insulin on prokallikrein synthesis and activation","volume":"80","author":"Jaffa","year":"1987","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.cbi.2023.110470_bib42","author":"Heydarigoojani"},{"key":"10.1016\/j.cbi.2023.110470_bib43","article-title":"Tissue factor, blood coagulation, and beyond: an overview","author":"Chu","year":"2011","journal-title":"Int. J. Inflamm."},{"issue":"3","key":"10.1016\/j.cbi.2023.110470_bib44","first-page":"1025","article-title":"Thrombin and plasmin activity in diabetes mellitus and their association with glycaemic control","volume":"65","author":"Small","year":"1987","journal-title":"QJM: Int. J. Med."},{"issue":"6","key":"10.1016\/j.cbi.2023.110470_bib45","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1681\/ASN.2015020208","article-title":"Cathepsin S cleavage of protease-activated receptor-2 on endothelial cells promotes microvascular diabetes complications","volume":"27","author":"VR","year":"2016","journal-title":"J. Am. Soc. Nephrol."},{"issue":"Pt 1","key":"10.1016\/j.cbi.2023.110470_bib46","first-page":"3","article-title":"Basolateral proteinase-activated receptor (PAR2) induces chloride secretion in M-1 mouse renal cortical collecting duct cells","volume":"521","author":"Bertog","year":"1999","journal-title":"Phys. J."},{"issue":"14","key":"10.1016\/j.cbi.2023.110470_bib47","doi-asserted-by":"crossref","first-page":"10124","DOI":"10.1074\/jbc.M112.446393","article-title":"Renal proteinase-activated receptor 2, a new actor in the control of blood pressure and plasma potassium level","volume":"288","author":"Morla","year":"2013","journal-title":"J. Biol. Chem."},{"issue":"6651","key":"10.1016\/j.cbi.2023.110470_bib48","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1038\/39329","article-title":"An epithelial serine protease activates the amiloride-sensitive sodium channel","volume":"389","author":"Vallet","year":"1997","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.cbi.2023.110470_bib49","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1111\/j.1523-1755.2005.00209.x","article-title":"Thrombin stimulates proinflammatory and proliferative responses in primary cultures of human proximal tubule cells","volume":"67","author":"Vesey","year":"2005","journal-title":"Kid int"},{"issue":"1","key":"10.1016\/j.cbi.2023.110470_bib50","first-page":"61","article-title":"Proteinase-activated receptor-2: physiological and pathophysiological roles","volume":"1","author":"Coelho","year":"2003","journal-title":"Curr. Med. Chem. Cardiovasc. Hematol. Agents"},{"issue":"1","key":"10.1016\/j.cbi.2023.110470_bib51","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1210\/er.2003-0025","article-title":"Proteinase-activated receptors: transducers of proteinase-mediated signaling in inflammation and immune response","volume":"26","author":"Steinhoff","year":"2005","journal-title":"Endocr. Rev."},{"issue":"1","key":"10.1016\/j.cbi.2023.110470_bib52","doi-asserted-by":"crossref","first-page":"256","DOI":"10.2741\/1796","article-title":"Role of tissue factor in thrombosis. Coagulation-inflammation-thrombosis circuit","volume":"11","author":"Chu","year":"2006","journal-title":"Front. Biosci."},{"issue":"12","key":"10.1016\/j.cbi.2023.110470_bib53","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.2215\/CJN.11491116","article-title":"Diabetic kidney disease: challenges, progress, and possibilities","volume":"12","author":"Alicic","year":"2017","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"10.1016\/j.cbi.2023.110470_bib54","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.cca.2019.07.005","article-title":"Mitochondrial dysfunction in diabetic kidney disease","volume":"496","author":"Wei","year":"2019","journal-title":"Clin. Chim. Acta"},{"issue":"1","key":"10.1016\/j.cbi.2023.110470_bib55","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/S1056-8727(00)00132-X","article-title":"Diabetes mellitus: a hypercoagulable state","volume":"15","author":"Carr","year":"2001","journal-title":"J. Diabetes Complicat."},{"issue":"2","key":"10.1016\/j.cbi.2023.110470_bib56","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.jphs.2017.09.002","article-title":"A protease-activated receptor-1 antagonist protects against podocyte injury in a mouse model of nephropathy","volume":"135","author":"Guan","year":"2017","journal-title":"J. Pharmacol. Sci."},{"issue":"Supplement_3","key":"10.1016\/j.cbi.2023.110470_bib57","doi-asserted-by":"crossref","first-page":"S109","DOI":"10.2337\/diab.45.3.S109","article-title":"Mechanism on disorders of coagulation and fibrinolysis in diabetes","volume":"45","author":"Matsuda","year":"1996","journal-title":"Diabetes"},{"issue":"14","key":"10.1016\/j.cbi.2023.110470_bib58","doi-asserted-by":"crossref","first-page":"7532","DOI":"10.3390\/ijms22147532","article-title":"Par2-induced tissue factor synthesis by primary cultures of human kidney tubular epithelial cells is modified by glucose availability","volume":"22","author":"Humphries","year":"2021","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.cbi.2023.110470_bib59","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1007\/s00210-021-02184-1","article-title":"Lack of miRNA-17 family mediates high glucose-induced PAR-1 upregulation in glomerular mesangial cells","volume":"395","author":"Tang","year":"2022","journal-title":"Naunyn-Schmiedeberg\u2019s Arch. Pharmacol."},{"issue":"1","key":"10.1016\/j.cbi.2023.110470_bib60","first-page":"107","article-title":"Implication of the MAPK signaling pathway in the pathogenesis of diabetic nephropathy","volume":"7","author":"Barros","year":"2019","journal-title":"Diabetes"},{"issue":"6","key":"10.1016\/j.cbi.2023.110470_bib61","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1038\/labinvest.3700549","article-title":"Renal p38 MAP kinase activity in experimental diabetes","volume":"87","author":"Komers","year":"2007","journal-title":"Lab. inv."},{"issue":"2","key":"10.1016\/j.cbi.2023.110470_bib62","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1038\/labinvest.3700502","article-title":"Roles of coagulation pathway and factor Xa in rat mesangioproliferative glomerulonephritis","volume":"87","author":"Nomura","year":"2007","journal-title":"Lab. inv."},{"issue":"8","key":"10.1016\/j.cbi.2023.110470_bib63","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.2337\/dc08-0282","article-title":"Hyperglycemia is associated with enhanced thrombin formation, platelet activation, and fibrin clot resistance to lysis in patients with acute coronary syndrome","volume":"31","author":"Undas","year":"2008","journal-title":"Diabetes Care"},{"issue":"1","key":"10.1016\/j.cbi.2023.110470_bib64","doi-asserted-by":"crossref","first-page":"202","DOI":"10.2337\/diabetes.55.01.06.db05-1026","article-title":"Effects of hyperglycemia and hyperinsulinemia on circulating tissue factor procoagulant activity and platelet CD40 ligand","volume":"55","author":"Vaidyula","year":"2006","journal-title":"Diabetes"},{"issue":"31","key":"10.1016\/j.cbi.2023.110470_bib65","doi-asserted-by":"crossref","DOI":"10.18632\/oncotarget.25069","article-title":"Vorapaxar treatment reduces mesangial expansion in streptozotocin-induced diabetic nephropathy in mice","volume":"9","author":"Waasdorp","year":"2018","journal-title":"Oncotarget"},{"issue":"4","key":"10.1016\/j.cbi.2023.110470_bib66","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1097\/MED.0000000000000074","article-title":"Early diabetic nephropathy in type 1 diabetes\u2013new insights","volume":"21","author":"Bjornstad","year":"2014","journal-title":"Curr. Opin. Endocrinol. Diabetes Obes."},{"issue":"3","key":"10.1016\/j.cbi.2023.110470_bib67","doi-asserted-by":"crossref","first-page":"439","DOI":"10.2337\/diabetes.47.3.439","article-title":"Predisposition to essential hypertension and development of diabetic nephropathy in IDDM patients","volume":"47","author":"Fagerudd","year":"1998","journal-title":"Diabetes"},{"issue":"5","key":"10.1016\/j.cbi.2023.110470_bib68","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1097\/01.ASN.0000065639.19190.CF","article-title":"Diabetic nephropathy in type 2 diabetes prevention and patient management","volume":"14","author":"Wolf","year":"2003","journal-title":"J. Am. Soc. Nephrol."},{"issue":"8","key":"10.1016\/j.cbi.2023.110470_bib69","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1161\/ATVBAHA.116.307883","article-title":"Coagulation factor Xa and protease-activated receptor 2 as novel therapeutic targets for diabetic nephropathy","volume":"36","author":"Oe","year":"2016","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"issue":"1","key":"10.1016\/j.cbi.2023.110470_bib70","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1007\/s00281-011-0289-1","article-title":"Protease-activated receptor 2 signaling in inflammation","volume":"34","author":"Rothmeier","year":"2012","journal-title":"Semin. Immunopathol."},{"issue":"52","key":"10.1016\/j.cbi.2023.110470_bib71","doi-asserted-by":"crossref","first-page":"37319","DOI":"10.1074\/jbc.M113.492793","article-title":"Proteinase-activated receptor-2 transactivation of epidermal growth factor receptor and transforming growth factor-\u03b2 receptor signaling pathways contributes to renal fibrosis","volume":"288","author":"Chung","year":"2013","journal-title":"J. Biol. Chem."},{"issue":"9","key":"10.1016\/j.cbi.2023.110470_bib72","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1055\/s-0037-1614040","article-title":"Macrophages synthesize factor X and secrete factor X\/Xa-containing prothrombinase activity into the surrounding medium","volume":"84","author":"Pejler","year":"2000","journal-title":"Thrombos. haemost."},{"issue":"10","key":"10.1016\/j.cbi.2023.110470_bib73","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1111\/j.1538-7836.2010.03976.x","article-title":"Elevated tissue factor expression contributes to exacerbated diabetic nephropathy in mice lacking eNOS fed a high fat diet","volume":"8","author":"Li","year":"2010","journal-title":"J. Thromb. Haemostasis"},{"issue":"10","key":"10.1016\/j.cbi.2023.110470_bib74","first-page":"4512","article-title":"Protease activated receptor 2 in diabetic nephropathy: a double-edged sword","volume":"9","author":"Waasdorp","year":"2017","journal-title":"Am. J. Trans. Res."},{"issue":"10","key":"10.1016\/j.cbi.2023.110470_bib75","doi-asserted-by":"crossref","first-page":"5255","DOI":"10.1073\/pnas.97.10.5255","article-title":"Tissue factor-and factor X-dependent activation of protease-activated receptor 2 by factor VIIa","volume":"97","author":"Camerer","year":"2000","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"5","key":"10.1016\/j.cbi.2023.110470_bib76","doi-asserted-by":"crossref","first-page":"F1067","DOI":"10.1152\/ajprenal.00595.2019","article-title":"Dual blockade of protease-activated receptor 1 and 2 additively ameliorates diabetic kidney disease","volume":"318","author":"Mitsui","year":"2020","journal-title":"Am. J. Physiol. Ren. Physiol."},{"issue":"3","key":"10.1016\/j.cbi.2023.110470_bib77","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1097\/MNH.0b013e3283451901","article-title":"Mouse models of diabetic nephropathy","volume":"20","author":"Alpers","year":"2011","journal-title":"Curr. Opin. Nephrol. Hypertens."},{"issue":"1","key":"10.1016\/j.cbi.2023.110470_bib78","doi-asserted-by":"crossref","first-page":"225","DOI":"10.2337\/diabetes.55.01.06.db05-0894","article-title":"Glucose-induced reactive oxygen species cause apoptosis of podocytes and podocyte depletion at the onset of diabetic nephropathy","volume":"55","author":"Susztak","year":"2006","journal-title":"Diabetes"},{"issue":"6","key":"10.1016\/j.cbi.2023.110470_bib79","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0157012","article-title":"Novel plasminogen activator inhibitor-1 inhibitors prevent diabetic kidney injury in a mouse model","volume":"11","author":"Jeong","year":"2016","journal-title":"PLoS One"},{"issue":"7","key":"10.1016\/j.cbi.2023.110470_bib80","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.2337\/db18-1075","article-title":"LRNA9884, a novel smad3-dependent long noncoding RNA, promotes diabetic kidney injury in db\/db mice via enhancing MCP-1\u2013dependent renal inflammation","volume":"68","author":"Zhang","year":"2019","journal-title":"Diabetes"},{"issue":"6","key":"10.1016\/j.cbi.2023.110470_bib81","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1681\/ASN.2014050489","article-title":"A single-gene cause in 29.5% of cases of steroid-resistant nephrotic syndrome","volume":"26","author":"Sadowski","year":"2015","journal-title":"J. Am. Soc. Nephrol."},{"issue":"3","key":"10.1016\/j.cbi.2023.110470_bib82","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/S0272-6386(12)80483-5","article-title":"Nephrotic proteinuria without hypoalbuminemia: clinical characteristics and response to angiotensin-converting enzyme inhibition","volume":"17","author":"Praga","year":"1991","journal-title":"Am. J. Kidney Dis."},{"issue":"1","key":"10.1016\/j.cbi.2023.110470_bib83","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12882-019-1336-8","article-title":"Prophylactic anticoagulation in nephrotic syndrome prevents thromboembolic complications","volume":"20","author":"Kelddal","year":"2019","journal-title":"BMC Nephrol."},{"issue":"9","key":"10.1016\/j.cbi.2023.110470_bib84","doi-asserted-by":"crossref","first-page":"2618","DOI":"10.1681\/ASN.2016070789","article-title":"Thrombin-induced podocyte injury is protease-activated receptor dependent","volume":"28","author":"Sharma","year":"2017","journal-title":"J. Am. Soc. Nephrol."},{"issue":"17","key":"10.1016\/j.cbi.2023.110470_bib85","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1056\/NEJM199804233381707","article-title":"The nephrotic syndrome","volume":"338","author":"Orth","year":"1998","journal-title":"N. Engl. J. Med."},{"issue":"11","key":"10.1016\/j.cbi.2023.110470_bib86","doi-asserted-by":"crossref","first-page":"4210","DOI":"10.1172\/JCI45161","article-title":"Cellular pathophysiology of ischemic acute kidney injury","volume":"121","author":"Bonventre","year":"2011","journal-title":"J. Clin. Invest."},{"issue":"6","key":"10.1016\/j.cbi.2023.110470_bib87","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1097\/TP.0b013e3181d72117","article-title":"Thrombin inhibition during kidney ischemia-reperfusion reduces chronic graft inflammation and tubular atrophy","volume":"90","author":"Thuillier","year":"2010","journal-title":"Transplantation"},{"issue":"3","key":"10.1016\/j.cbi.2023.110470_bib88","doi-asserted-by":"crossref","first-page":"513","DOI":"10.2215\/CJN.10131011","article-title":"Epidemiology and pathophysiology of nephrotic syndrome\u2013associated thromboembolic disease","volume":"7","author":"Kerlin","year":"2012","journal-title":"Clin. J. Am. Soc. Nephrol."},{"issue":"2","key":"10.1016\/j.cbi.2023.110470_bib89","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1111\/j.1523-1755.2005.67102.x","article-title":"MEK inhibitor, U0126, attenuates cisplatin-induced renal injury by decreasing inflammation and apoptosis","volume":"67","author":"Jo","year":"2005","journal-title":"Kidney Int."},{"issue":"3","key":"10.1016\/j.cbi.2023.110470_bib90","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1182\/blood-2011-07-365973","article-title":"Cytoprotective signaling by activated protein C requires protease-activated receptor-3 in podocytes","volume":"119","author":"Madhusudhan","year":"2012","journal-title":"Blood: J. Am. Soc. Hematol."},{"issue":"5","key":"10.1016\/j.cbi.2023.110470_bib91","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1002\/path.4149","article-title":"Active proteases in nephrotic plasma lead to a podocin\u2010dependent phosphorylation of VASP in podocytes via protease activated receptor\u20101","volume":"229","author":"Harris","year":"2013","journal-title":"J. Pathol."},{"issue":"3","key":"10.1016\/j.cbi.2023.110470_bib92","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.pharmthera.2009.05.004","article-title":"Vergnolle N Protease-activated receptors as drug targets in inflammation and pain","volume":"123","year":"2009","journal-title":"Pharmacol. Ther."},{"issue":"9","key":"10.1016\/j.cbi.2023.110470_bib93","doi-asserted-by":"crossref","first-page":"5315","DOI":"10.4049\/jimmunol.169.9.5315","article-title":"Protease-activated receptor 2 mediates eosinophil infiltration and hyper reactivity in allergic inflammation of the airway","volume":"169","author":"Schmidlin","year":"2002","journal-title":"J. Immunol."},{"issue":"9","key":"10.1016\/j.cbi.2023.110470_bib94","doi-asserted-by":"crossref","first-page":"2809","DOI":"10.1002\/jcb.25930","article-title":"Calcium uptake via mitochondrial uniporter contributes to palmitic acid\u2010induced apoptosis in mouse podocytes","volume":"118","author":"Yuan","year":"2017","journal-title":"J. Cell. Biochem."},{"issue":"5","key":"10.1016\/j.cbi.2023.110470_bib95","doi-asserted-by":"crossref","first-page":"2050","DOI":"10.1172\/JCI71702","article-title":"Intravital imaging of podocyte calcium in glomerular injury and disease","volume":"124","author":"Burford","year":"2014","journal-title":"J. Clin. Investig."},{"issue":"11","key":"10.1016\/j.cbi.2023.110470_bib96","doi-asserted-by":"crossref","first-page":"4210","DOI":"10.1172\/JCI45161","article-title":"Cellular pathophysiology of ischemic acute kidney injury","volume":"121","author":"Bonventre","year":"2011","journal-title":"J. Clin. Investig."},{"issue":"1","key":"10.1016\/j.cbi.2023.110470_bib97","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-019-39914-8","article-title":"Protease-activated receptor 2 protects against VEGF inhibitor-induced glomerular endothelial and podocyte injury","volume":"9","author":"Oe","year":"2019","journal-title":"Sci. Rep."},{"issue":"11","key":"10.1016\/j.cbi.2023.110470_bib98","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1056\/NEJMoa0707330","article-title":"VEGF inhibition and renal thrombotic microangiopathy","volume":"358","author":"Eremina","year":"2008","journal-title":"NEJM"},{"issue":"6","key":"10.1016\/j.cbi.2023.110470_bib99","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1111\/j.1523-1755.2004.00621.x","article-title":"The role of vascular endothelial growth factor (VEGF) in renal pathophysiology","volume":"65","author":"Schrijvers","year":"2004","journal-title":"Kid. int."},{"issue":"4","key":"10.1016\/j.cbi.2023.110470_bib100","doi-asserted-by":"crossref","DOI":"10.1007\/s11912-012-0242-z","article-title":"VEGF inhibition, hypertension, and renal toxicity","volume":"14","author":"Hayman","year":"2012","journal-title":"Curr. Oncol. Rep."},{"issue":"2","key":"10.1016\/j.cbi.2023.110470_bib101","first-page":"172","article-title":"Renal side effects of VEGF-blocking therapy","volume":"3","author":"M\u00fcller-Deile","year":"2010","journal-title":"NDT plus"},{"key":"10.1016\/j.cbi.2023.110470_bib102","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1146\/annurev-physiol-021115-105412","article-title":"Vascular growth factors and glomerular disease","volume":"78","author":"Bartlett","year":"2016","journal-title":"Annu. Rev. Physiol."},{"key":"10.1016\/j.cbi.2023.110470_bib103","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1038\/ki.2014.17","article-title":"Advances in the pathophysiology of pre-eclampsia and related podocyte injury","volume":"86","author":"Craici","year":"2014","journal-title":"Kidney Int."},{"issue":"1","key":"10.1016\/j.cbi.2023.110470_bib104","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/s10059-013-0140-8","article-title":"Autophagy: a critical regulator of cellular metabolism and homeostasis","volume":"36","author":"Ryter","year":"2013","journal-title":"Mol. Cell"},{"issue":"9","key":"10.1016\/j.cbi.2023.110470_bib105","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1038\/s41581-020-0309-2","article-title":"Autophagy in kidney homeostasis and disease","volume":"16","author":"Tang","year":"2020","journal-title":"Nat. Rev. Nephrol."},{"issue":"1","key":"10.1016\/j.cbi.2023.110470_bib106","first-page":"1","article-title":"Hirudin, a thrombin inhibitor, attenuates TGF-\u03b2-induced fibrosis in renal proximal tubular epithelial cells by inhibition of protease-activated receptor 1 expression via S1P\/S1PR2\/S1PR3 signaling","volume":"23","author":"Lin","year":"2022","journal-title":"Exp. Ther. Med."},{"issue":"2","key":"10.1016\/j.cbi.2023.110470_bib107","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1136\/thoraxjnl-2011-200026","article-title":"Sphingosine-1-phosphate is increased in patients with idiopathic pulmonary fibrosis and mediates epithelial to mesenchymal transition","volume":"67","author":"Milara","year":"2012","journal-title":"Thorax"},{"issue":"21","key":"10.1016\/j.cbi.2023.110470_bib108","doi-asserted-by":"crossref","first-page":"2873","DOI":"10.1042\/CS20200923","article-title":"The PAR-1 antagonist vorapaxar ameliorates kidney injury and tubulointerstitial fibrosis","volume":"134","author":"Lok","year":"2020","journal-title":"Clin. Sci."},{"issue":"5","key":"10.1016\/j.cbi.2023.110470_bib109","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1053\/j.ackd.2014.04.001","article-title":"Mechanisms of disease reversal in focal and segmental glomerulosclerosis","volume":"21","author":"Yang","year":"2014","journal-title":"Adv. Chron. Kidney Dis."},{"issue":"5","key":"10.1016\/j.cbi.2023.110470_bib110","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1053\/j.ackd.2011.03.005","article-title":"Focal segmental glomerulosclerosis and chronic kidney disease in pediatric patients","volume":"18","author":"Kiffel","year":"2011","journal-title":"Adv. Chron. Kidney Dis."},{"issue":"3","key":"10.1016\/j.cbi.2023.110470_bib111","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1080\/14728214.2020.1803276","article-title":"Emerging drugs for treatment of focal segmental glomerulosclerosis","volume":"25","author":"Trachtman","year":"2020","journal-title":"Expet Opin. Emerg. Drugs"},{"issue":"1","key":"10.1016\/j.cbi.2023.110470_bib112","article-title":"Histologic variants of FSGS: an epidemiological and pathological perspective","volume":"5","author":"Shakeel","year":"2021","journal-title":"PJKD"},{"issue":"3","key":"10.1016\/j.cbi.2023.110470_bib113","doi-asserted-by":"crossref","first-page":"502","DOI":"10.2215\/CJN.05960616","article-title":"Focal segmental glomerulosclerosis","volume":"12","author":"Rosenberg","year":"2017","journal-title":"Clin. J. Am. Soc. Nephrol."},{"issue":"3","key":"10.1016\/j.cbi.2023.110470_bib114","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1159\/000464121","article-title":"Role of protease-activated receptor 2 in regulating focal segmental glomerulosclerosis","volume":"41","author":"Wang","year":"2017","journal-title":"Cell. Physiol. Biochem."},{"issue":"9","key":"10.1016\/j.cbi.2023.110470_bib115","doi-asserted-by":"crossref","first-page":"5882","DOI":"10.1128\/MCB.19.9.5882","article-title":"Protein kinase A-dependent and-independent signaling pathways contribute to cyclic AMP-stimulated proliferation","volume":"19","author":"Cass","year":"1999","journal-title":"Mol. Cell Biol."},{"issue":"5","key":"10.1016\/j.cbi.2023.110470_bib116","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1111\/j.1440-1797.2006.00673.x","article-title":"Protein kinase C activation and its role in kidney disease","volume":"11","author":"Li","year":"2006","journal-title":"Nephrology"},{"key":"10.1016\/j.cbi.2023.110470_bib117","doi-asserted-by":"crossref","DOI":"10.1016\/j.ecoenv.2020.111480","article-title":"Cadmium induces epithelial\u2013mesenchymal transition and migration of renal cancer cells by increasing PGE2 through a cAMP\/PKA-COX2 dependent mechanism","volume":"207","author":"Shi","year":"2021","journal-title":"Ecotoxicol. Environ. Saf."},{"issue":"3","key":"10.1016\/j.cbi.2023.110470_bib118","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1016\/j.bbrc.2015.02.022","article-title":"C-peptide ameliorates renal injury in type 2 diabetic rats through protein kinase A-mediated inhibition of fibronectin synthesis","volume":"458","author":"Xu","year":"2015","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"6","key":"10.1016\/j.cbi.2023.110470_bib119","doi-asserted-by":"crossref","first-page":"F718","DOI":"10.1152\/ajprenal.00372.2013","article-title":"Renal PKC-\u03b5 deficiency attenuates acute kidney injury and ischemic allograft injury via TNF-\u03b1-dependent inhibition of apoptosis and inflammation","volume":"307","author":"Rong","year":"2014","journal-title":"Am. J. Physiol. Ren. Physiol."},{"issue":"1","key":"10.1016\/j.cbi.2023.110470_bib120","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.yexcr.2004.08.004","article-title":"Desmin: a major intermediate filament protein essential for the structural integrity and function of muscle","volume":"301","author":"Paulin","year":"2004","journal-title":"Exp. Cell Res."},{"issue":"4","key":"10.1016\/j.cbi.2023.110470_bib121","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1007\/s00428-005-0134-9","article-title":"Upregulation of nestin, vimentin, and desmin in rat podocytes in response to injury","volume":"448","author":"Zou","year":"2006","journal-title":"Virchows Arch."},{"issue":"2","key":"10.1016\/j.cbi.2023.110470_bib122","doi-asserted-by":"crossref","first-page":"73","DOI":"10.5414\/CNP68073","article-title":"Desmin as a marker of proteinuria in early stages of membranous nephropathy in elderly patients","volume":"68","author":"Maruyama","year":"2007","journal-title":"Clin. Nephrol."},{"key":"10.1016\/j.cbi.2023.110470_bib123","doi-asserted-by":"crossref","first-page":"123","DOI":"10.3389\/fcell.2020.00123","article-title":"Diverse role of TGF-\u03b2 in kidney disease","volume":"8","author":"Gu","year":"2020","journal-title":"Front. Cell Dev. Biol."},{"key":"10.1016\/j.cbi.2023.110470_bib124","article-title":"Differential role of mesangial cells and podocytes in TGF-\u00df-induced mesangial matrix synthesis in chronic glomerular disease","author":"Lee","year":"2009","journal-title":"Histol. Histopathol."},{"issue":"3","key":"10.1016\/j.cbi.2023.110470_bib125","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1002\/(SICI)1096-9896(199911)189:3<425::AID-PATH454>3.0.CO;2-6","article-title":"mRNA expression of glomerular basement membrane proteins and TGF\u2010\u03b2 1 in human membranous nephropathy","volume":"189","author":"Kim","year":"1999","journal-title":"J. Pathol."},{"issue":"2","key":"10.1016\/j.cbi.2023.110470_bib126","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/S0092-8674(00)00121-5","article-title":"TGF\u03b2 signaling in growth control, cancer, and heritable disorders","volume":"103","author":"Massagu\u00e9","year":"2000","journal-title":"Cell"},{"issue":"4","key":"10.1016\/j.cbi.2023.110470_bib127","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1681\/ASN.2004070593","article-title":"Focal and segmental glomerulosclerosis: definition and relevance of a partial remission","volume":"16","author":"Troyanov","year":"2005","journal-title":"J. Am. Soc. Nephrol."},{"issue":"2","key":"10.1016\/j.cbi.2023.110470_bib128","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1053\/snep.2003.50020","article-title":"Angiotensin antagonists and steroids in the treatment of focal segmental glomerulosclerosis","volume":"23","author":"Korbet","year":"2003","journal-title":"Semin. Nephrol."},{"issue":"3","key":"10.1016\/j.cbi.2023.110470_bib129","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/s12272-022-01375-5","article-title":"Renal tubular PAR2 promotes interstitial fibrosis by increasing inflammatory responses and EMT process","volume":"45","author":"Ha","year":"2022","journal-title":"Arch Pharm. Res. (Seoul)"},{"issue":"1","key":"10.1016\/j.cbi.2023.110470_bib130","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/nep.13180","article-title":"Adenine\u2010induced chronic kidney disease in rats","volume":"23","author":"Diwan","year":"2018","journal-title":"Nephrology"},{"key":"10.1016\/j.cbi.2023.110470_bib131","doi-asserted-by":"crossref","first-page":"i1585","DOI":"10.1136\/bmj.i1585","article-title":"Sepsis: pathophysiology and clinical management","volume":"353","author":"Gotts","year":"2016","journal-title":"BMJ"},{"issue":"3","key":"10.1016\/j.cbi.2023.110470_bib132","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1007\/s40620-017-0452-4","article-title":"Recent advances in the pathogenetic mechanisms of sepsis-associated acute kidney injury","volume":"31","author":"Fani","year":"2018","journal-title":"J. Nephrol."},{"issue":"10","key":"10.1016\/j.cbi.2023.110470_bib133","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1038\/nri2402","article-title":"Harmful molecular mechanisms in sepsis","volume":"8","author":"Rittirsch","year":"2008","journal-title":"Nat. Rev. Immunol."},{"issue":"4","key":"10.1016\/j.cbi.2023.110470_bib134","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/cc10332","article-title":"The late phase of sepsis is characterized by an increased microbiological burden and death rate","volume":"15","author":"Otto","year":"2011","journal-title":"Crit. Care"},{"issue":"10","key":"10.1016\/j.cbi.2023.110470_bib135","doi-asserted-by":"crossref","first-page":"2868","DOI":"10.1172\/JCI39421","article-title":"Animal models of sepsis and sepsis-induced kidney injury","volume":"119","author":"Doi","year":"2009","journal-title":"J. Clin. Invest."},{"issue":"5","key":"10.1016\/j.cbi.2023.110470_bib136","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1080\/00984109708984034","article-title":"Pathobiology of lipopolysaccharide","volume":"51","author":"Mayeux","year":"1997","journal-title":"J. Toxicol. Environ. Health"},{"issue":"9","key":"10.1016\/j.cbi.2023.110470_bib137","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1097\/01.CCM.0000138558.16257.3F","article-title":"Persistent-microcirculatory alterations are associated with organ failure and death in patients with septic shock","volume":"32","author":"Sakr","year":"2004","journal-title":"Crit. Care Med."},{"issue":"8","key":"10.1016\/j.cbi.2023.110470_bib138","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1007\/s00134-013-2982-0","article-title":"Effects of dobutamine on systemic, regional and microcirculatory perfusion parameters in septic shock: a randomized, placebo-controlled, double-blind, crossover study","volume":"39","author":"Hernandez","year":"2013","journal-title":"Intensive Care Med."},{"key":"10.1016\/j.cbi.2023.110470_bib139","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1007\/s00134-008-1367-2","article-title":"Acute kidney injury in septic shock: clinical outcomes and impact of duration of hypotension prior to initiation of antimicrobial therapy","volume":"35","author":"Bagshaw","year":"2009","journal-title":"Intensive Care Med."},{"key":"10.1016\/j.cbi.2023.110470_bib140","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1056\/NEJMoa1500896","article-title":"Trial of early, goal-directed resuscitation for septic shock","volume":"372","author":"Mouncey","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.cbi.2023.110470_bib141","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1097\/ALN.0000000000000861","article-title":"Association between initial fluid choice and subsequent in-hospital mortality during the resuscitation of adults with septic shock","volume":"123","author":"Raghunathan","year":"2015","journal-title":"Anesthesiology"},{"issue":"4","key":"10.1016\/j.cbi.2023.110470_bib142","doi-asserted-by":"crossref","first-page":"F542","DOI":"10.1152\/ajprenal.1993.265.4.F542","article-title":"Endothelin-1 mRNA in glomerular and epithelial cells of kidney","volume":"265","author":"Chen","year":"1993","journal-title":"Am. J. Physiol. Ren. Physiol."},{"issue":"1","key":"10.1016\/j.cbi.2023.110470_bib143","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1097\/MNH.0000000000000185","article-title":"Endothelin-1 and the kidney: new perspectives and recent findings","volume":"25","author":"De Miguel","year":"2016","journal-title":"Curr. Opin. Nephrol. Hypertens."},{"issue":"2","key":"10.1016\/j.cbi.2023.110470_bib144","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.lfs.2014.03.013","article-title":"Effects of protease activated receptor (PAR) 2 blocking peptide on endothelin-1 levels in kidney tissues in endotoxemic rat model","volume":"102","author":"Jesmin","year":"2014","journal-title":"Life Sci."},{"issue":"2","key":"10.1016\/j.cbi.2023.110470_bib145","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1159\/000366127","article-title":"Survey of acute kidney injury and related risk factors of mortality in hospitalized patients in a third-level urban hospital of Shanghai","volume":"38","author":"Lu","year":"2014","journal-title":"Blood Purif."},{"issue":"2","key":"10.1016\/j.cbi.2023.110470_bib146","doi-asserted-by":"crossref","first-page":"52","DOI":"10.5500\/wjt.v5.i2.52","article-title":"Update on ischemia-reperfusion injury in kidney transplantation: pathogenesis and treatment","volume":"5","author":"Salvadori","year":"2015","journal-title":"World J. Transplant."},{"issue":"4","key":"10.1016\/j.cbi.2023.110470_bib147","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1681\/ASN.2005091017","article-title":"Declining mortality in patients with acute renal failure, 1988 to 2002","volume":"17","author":"Waikar","year":"2006","journal-title":"J. Am. Soc. Nephrol."},{"issue":"1","key":"10.1016\/j.cbi.2023.110470_bib148","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1681\/ASN.2012080800","article-title":"Temporal changes in incidence of dialysis-requiring AKI","volume":"24","author":"Hsu","year":"2013","journal-title":"J. Am. Soc. Nephrol."},{"issue":"3","key":"10.1016\/j.cbi.2023.110470_bib149","doi-asserted-by":"crossref","first-page":"520","DOI":"10.2215\/CJN.06711208","article-title":"The nexus of acute kidney injury, chronic kidney disease, and World Kidney Day 2009","volume":"4","author":"Okusa","year":"2009","journal-title":"Clin. J. Am. Soc. Nephrol."},{"issue":"2","key":"10.1016\/j.cbi.2023.110470_bib150","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1038\/nrneph.2015.177","article-title":"The emerging role of coagulation proteases in kidney disease","volume":"12","author":"Madhusudhan","year":"2016","journal-title":"Nat. Rev. Nephrol."},{"key":"10.1016\/j.cbi.2023.110470_bib151","article-title":"Dual role of protease activated receptor 4 in acute kidney injury: contributing to renal injury and inflammation, while maintaining the renal filtration barrier upon acute renal ischemia reperfusion injury","author":"Jansen","year":"2019","journal-title":"bioRxiv"},{"key":"10.1016\/j.cbi.2023.110470_bib152","first-page":"2021","article-title":"Protease-activated receptor 1 contributes to microcirculation failure and tubular damage in renal ischemia-reperfusion injury in mice","author":"Guan","year":"2021","journal-title":"BioMed Res. Int."},{"issue":"4","key":"10.1016\/j.cbi.2023.110470_bib153","doi-asserted-by":"crossref","first-page":"221","DOI":"10.5114\/reum.2019.87619","article-title":"Systemic sclerosis\u2013multidisciplinary disease: clinical features and treatment","volume":"57","author":"Sobolewski","year":"2019","journal-title":"Reumatologia"},{"issue":"3","key":"10.1016\/j.cbi.2023.110470_bib154","doi-asserted-by":"crossref","first-page":"201","DOI":"10.2174\/157436209789057467","article-title":"Targeting JAK\/STAT signaling pathway in inflammatory diseases","volume":"4","author":"Malemud","year":"2009","journal-title":"Curr. Signal Transduct. Ther."},{"key":"10.1016\/j.cbi.2023.110470_bib155","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1007\/s40265-015-0387-9","article-title":"Vorapaxar: a review of its use in the long-term secondary prevention of atherothrombotic events","volume":"75","author":"Frampton","year":"2015","journal-title":"Drugs"},{"issue":"1\u20133","key":"10.1016\/j.cbi.2023.110470_bib156","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.ejphar.2011.01.058","article-title":"The novel and orally active thrombin receptor antagonist E5555 (Atopaxar) inhibits arterial thrombosis without affecting bleeding time in Guinea pigs","volume":"657","author":"Kogushi","year":"2011","journal-title":"Eur. J. Pharmacol."},{"issue":"7","key":"10.1016\/j.cbi.2023.110470_bib157","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1056\/NEJMoa1711948","article-title":"Edoxaban for the treatment of cancer-associated venous thromboembolism","volume":"378","author":"Raskob","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.cbi.2023.110470_bib158","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1055\/s-0038-1646530","article-title":"Recombinant desulphatohirudin (CGP 39393) anticoagulant and antithrombotic properties in vivo","volume":"61","author":"Talbot","year":"1989","journal-title":"Thromb. Haemostasis"},{"issue":"6","key":"10.1016\/j.cbi.2023.110470_bib159","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1016\/0003-4975(94)91661-6","article-title":"Evaluation of CGP 39393 as the anticoagulant in cardiopulmonary bypass operation in a dog model","volume":"58","author":"Walenga","year":"1994","journal-title":"Ann. Thorac. Surg."},{"issue":"2","key":"10.1016\/j.cbi.2023.110470_bib160","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1620\/tjem.249.127","article-title":"Glomerular injury is exacerbated in Lupus-Prone MRL\/lpr mice treated with a protease-activated receptor 2 antagonist","volume":"249","author":"Itto","year":"2019","journal-title":"Tohoku J. Exp. Med."},{"issue":"11","key":"10.1016\/j.cbi.2023.110470_bib161","doi-asserted-by":"crossref","first-page":"2678","DOI":"10.1161\/ATVBAHA.120.314960","article-title":"Antithrombotic effects of combined PAR (Protease-Activated receptor)-4 antagonism and factor Xa inhibition","volume":"40","author":"Meah","year":"2020","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"issue":"Supplement_2","key":"10.1016\/j.cbi.2023.110470_bib162","doi-asserted-by":"crossref","first-page":"ehaa946","DOI":"10.1093\/ehjci\/ehaa946.3380","article-title":"Favorable therapeutic index of an orally-active small-molecule antagonist of the platelet protease-activated receptor-4, BMS-986141, compared with the P2Y12 antagonist ticagrelor in cynomolgus monkeys","volume":"41","author":"Wong","year":"2020","journal-title":"Eur. Heart J."}],"container-title":["Chemico-Biological Interactions"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009279723001370?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009279723001370?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,14]],"date-time":"2025-09-14T14:14:09Z","timestamp":1757859249000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0009279723001370"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5]]},"references-count":162,"alternative-id":["S0009279723001370"],"URL":"https:\/\/doi.org\/10.1016\/j.cbi.2023.110470","relation":{},"ISSN":["0009-2797"],"issn-type":[{"value":"0009-2797","type":"print"}],"subject":[],"published":{"date-parts":[[2023,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Protease-activated receptors in kidney diseases: A comprehensive review of pathological roles, therapeutic outcomes and challenges","name":"articletitle","label":"Article Title"},{"value":"Chemico-Biological Interactions","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cbi.2023.110470","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"110470"}}